Login

Liquidia stock dropped after a US federal court ruled that Liquidia's Yutrepia lung drug infringes two claims of a United Therapeutics patent. The ruling now affects commercial outlook of Yutrepia. Liquidia plans to pursue appellate options and ask the US FDA to remove the PH-ILD indication from the drug's label. The final judgment will come within a week.